Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q2070286> ?p ?o }
Showing triples 1 to 62 of
62
with 100 triples per page.
- Q2070286 subject Q7335370.
- Q2070286 subject Q8297678.
- Q2070286 subject Q8862272.
- Q2070286 subject Q8919936.
- Q2070286 abstract "Vismodegib (trade name Erivedge) is a drug for the treatment of basal-cell carcinoma (BCC). The approval of vismodegib on January 30, 2012, represents the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration (FDA) approval. The drug is also undergoing clinical trials for metastatic colorectal cancer, small-cell lung cancer, advanced stomach cancer, pancreatic cancer, medulloblastoma and chondrosarcoma as of Template:MONTHNAME 2011[[Category:Articles containing potentially dated statements from Template:MONTHNAME 2011]]. The drug was developed by the biotechnology/pharmaceutical company Genentech, which is headquartered at South San Francisco, California, USA.".
- Q2070286 atcPrefix "L01".
- Q2070286 atcSuffix "XX43".
- Q2070286 bioavailability "31.8".
- Q2070286 casNumber "879085-55-9".
- Q2070286 chEBI "66903".
- Q2070286 drugbank "DB08828".
- Q2070286 fdaUniiCode "25X868M3DS".
- Q2070286 iupacName "2-Chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide".
- Q2070286 pubchem "24776445".
- Q2070286 thumbnail Vismodegib2DACS.svg?width=300.
- Q2070286 wikiPageExternalLink fda-vismodegib.
- Q2070286 wikiPageExternalLink www.erivedge.com.
- Q2070286 wikiPageExternalLink NEJMoa1113713.
- Q2070286 wikiPageWikiLink Q1076087.
- Q2070286 wikiPageWikiLink Q12140.
- Q2070286 wikiPageWikiLink Q1333608.
- Q2070286 wikiPageWikiLink Q14864419.
- Q2070286 wikiPageWikiLink Q14886430.
- Q2070286 wikiPageWikiLink Q14886491.
- Q2070286 wikiPageWikiLink Q14916181.
- Q2070286 wikiPageWikiLink Q17912018.
- Q2070286 wikiPageWikiLink Q18031607.
- Q2070286 wikiPageWikiLink Q188874.
- Q2070286 wikiPageWikiLink Q189588.
- Q2070286 wikiPageWikiLink Q204711.
- Q2070286 wikiPageWikiLink Q212961.
- Q2070286 wikiPageWikiLink Q30.
- Q2070286 wikiPageWikiLink Q3271319.
- Q2070286 wikiPageWikiLink Q410943.
- Q2070286 wikiPageWikiLink Q6402731.
- Q2070286 wikiPageWikiLink Q7108.
- Q2070286 wikiPageWikiLink Q7335370.
- Q2070286 wikiPageWikiLink Q738170.
- Q2070286 wikiPageWikiLink Q809758.
- Q2070286 wikiPageWikiLink Q8297678.
- Q2070286 wikiPageWikiLink Q8862272.
- Q2070286 wikiPageWikiLink Q8919936.
- Q2070286 wikiPageWikiLink Q899140.
- Q2070286 wikiPageWikiLink Q903852.
- Q2070286 wikiPageWikiLink Q927122.
- Q2070286 atcPrefix "L01".
- Q2070286 atcSuffix "XX43".
- Q2070286 bioavailability "31.8".
- Q2070286 casNumber "879085".
- Q2070286 chebi "66903".
- Q2070286 drugbank "DB08828".
- Q2070286 iupacName "2".
- Q2070286 pubchem "24776445".
- Q2070286 unii "25".
- Q2070286 type ChemicalSubstance.
- Q2070286 type Drug.
- Q2070286 type ChemicalObject.
- Q2070286 type Thing.
- Q2070286 type Q8386.
- Q2070286 comment "Vismodegib (trade name Erivedge) is a drug for the treatment of basal-cell carcinoma (BCC). The approval of vismodegib on January 30, 2012, represents the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration (FDA) approval.".
- Q2070286 label "Vismodegib".
- Q2070286 depiction Vismodegib2DACS.svg.